FDA Approves Auvelity for Agitation in Alzheimer’s Disease - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

  • By

  • Kathryn Wighton

  • April 30, 2026

  • 3 min

Share

Objective:

To report the FDA approval of Auvelity for treating agitation associated with Alzheimer's disease.

Approach:
    Key Findings:
    • Agitation affects up to 76% of Alzheimer's patients.
    • Dextromethorphan-bupropion significantly improved agitation symptoms in clinical trials.
    • The treatment has a specific dosing regimen for agitation in Alzheimer's, differing from major depressive disorder.
    Interpretation:

    The approval of Auvelity provides a new treatment option for managing agitation in Alzheimer's patients, addressing a significant symptom that affects quality of life.

    Limitations:
    • The mechanism of action for agitation treatment remains unclear.
    • The relapse findings in ACCORD-2 should be interpreted with caution due to prior responder enrollment.
    Conclusion:

    Auvelity's approval represents a significant advancement in the treatment of agitation in Alzheimer's disease, with specific dosing and safety considerations.

    Sources:

Original Source(s)

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

  • by Kathryn Wighton

  • April 30, 2026

Related Content

Medical Oddities: When a Brush Beats a Scalpel

This research roundup has brain drama, bleeding control, skin science, and tiny brushes.

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Medical Oddities: Could multilingualism keep you young?

From multilingual minds to pomegranate hearts, gastric mischief, and swishable tea, science stays delightfully odd.